Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Rises By 23.7%

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 102,200 shares, an increase of 23.7% from the October 31st total of 82,600 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average daily volume of 77,300 shares, the days-to-cover ratio is presently 1.3 days.

VYNE Therapeutics Stock Up 0.3 %

Shares of VYNE opened at $2.96 on Monday. The business has a 50-day simple moving average of $2.48 and a two-hundred day simple moving average of $2.20. VYNE Therapeutics has a 52 week low of $1.57 and a 52 week high of $3.66. The stock has a market cap of $43.66 million, a price-to-earnings ratio of -3.44 and a beta of 1.32.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP purchased a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics makes up about 0.0% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 17th biggest position. Lynx1 Capital Management LP owned 0.11% of VYNE Therapeutics as of its most recent SEC filing. 83.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on VYNE shares. BTIG Research began coverage on shares of VYNE Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $8.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $5.75 price target on shares of VYNE Therapeutics in a research note on Friday, November 8th.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.